Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13078874 | 0.89 | METAP2 (0.32) | METAP2 | |
| SCHEMBL3508077 | 0.80 | METAP2 (0.45) | METAP2 | |
| SCHEMBL5612785 | 0.78 | RPA1 (0.44) | METAP2 | |
| SCHEMBL20848 | 0.78 | KMT2A (0.44) | METAP2 | |
| SCHEMBL3283468 | 0.78 | — | — | |
| SCHEMBL1823584 | 0.78 | METAP2 (0.44) | METAP2 | |
| SCHEMBL105252 | 0.78 | RAB9A (0.40) | — | |
| SCHEMBL12989702 | 0.78 | AKT1 (0.48) | METAP2 | |
| SCHEMBL718333 | 0.78 | MAPT (0.45) | APP | |
| SCHEMBL6945194 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143578-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2005-06-30 | — | — | US | claimed |
| EP-1434772-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2005-05-04 | — | — | EP | claimed |
| US-20040192914-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | claimed |
| EP-1434772-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2004-07-07 | — | — | EP | claimed |
| WO-2003031434-A1 | COMPOUNDS AND METHODS | SMITH KLINE BEECHAM CORPORATION (US) | 2003-04-17 | — | — | WO | claimed |
| US-20050143578-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2005-06-30 | — | — | US | disclosed |
| EP-1434772-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2005-05-04 | — | — | EP | disclosed |
| US-20040192914-A1 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION | 2004-09-30 | — | — | US | disclosed |
| EP-1434772-A1 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003031434-A1 | COMPOUNDS AND METHODS | SMITH KLINE BEECHAM CORPORATION (US) | 2003-04-17 | — | — | WO | disclosed |
| CN-1093536-C | 5-lipoxygenase inhibitors | PFIZER (US) | 2002-10-30 | — | — | CN | disclosed |
| EP-0787127-B1 | 5-LIPOXYGENASE INHIBITORS | PFIZER (US) | 2001-01-03 | — | — | EP | disclosed |
| US-5883106-A | 5-lipoxygenase inhibitors | PFIZER INC. (US) | 1999-03-16 | — | — | US | disclosed |
| CN-1169722-A | 5-lipoxygenase inhibitors | PFIZER (US) | 1998-01-07 | — | — | CN | disclosed |
| EP-0787127-A1 | 5-LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1997-08-06 | — | — | EP | disclosed |
| EP-0679647-B1 | Novel antifungal triazole compound and production and use thereof | NIHON NOHYAKU CO LTD (JP) | 1997-06-04 | — | — | EP | disclosed |
| US-5629332-A | FUNGICIDES | NIHON NOHYAKU CO., LTD. (JP) | 1997-05-13 | — | — | US | disclosed |
| WO-1996011911-A1 | 5-LIPOXYGENASE INHIBITORS | PFIZER INC. (US) | 1996-04-25 | — | — | WO | disclosed |
| CN-1112113-A | Novel triazole compound and production process and use thereof | NIHON NOHYAKU CO LTD (JP) | 1995-11-22 | — | — | CN | disclosed |
| EP-0679647-A1 | Novel antifungal triazole compound and production and use thereof | NIHON NOHYAKU CO., LTD. (JP) | 1995-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192914-A1 | Compounds and methods | METAP2, METAP1, DNPEP | METAP2 1/4885MAP2K1 4019/4885APP 951/4885 |
| US-20050143578-A1 | Compounds and methods | METAP2, METAP1, DNPEP | METAP2 1/4885MAP2K1 3890/4885APP 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.